ArticlePloS one2025
Global, regional, and national burden of leukemia: Epidemiological trends analysis from 1990 to 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Geriatric oncology at a crossroads: Advancing equity and access for elderly leukemia patients in underserved regions.Translational oncology · 2026Review
- Therapeutic Potential of Ginger Rhizomes (Zingiber officinale) on Leukemia.Biotechnology and applied biochemistry · 2026Review
- Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment.Cells · 2026Review
- Leukemia disease burden and quality of care among adolescents and young adults in China compared to global patterns: a comprehensive analysis from 1990 to 2021.Frontiers in public health · 2026Article
- Late-stage leukemias in aging populations: a public health call for integrated and personalized care models.Annals of medicine and surgery (2012) · 2026Review
- Article
- Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Network pharmacology, molecular docking, and experimental validation-based approach to explore the mechanism of action of ginsenoside Rh4 on acute myeloid leukemia cells.Medical oncology (Northwood, London, England) · 2025Article
- Leukemia Incidence and Demographic Trends in Saudi Arabia, 1997-2022: A Nationwide Registry Analysis.Journal of epidemiology and global health · 2025Article
- Diseases burden and trends of bladder cancer attributable to behavioral and metabolic factors among global and Chinese population, 1990-2021: results from the global burden of disease study 2021.Journal of health, population, and nutrition · 2025Article
- Therapeutic implications of vitamin D in leukemia: mechanistic and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukemia is a prevalent form of cancer that encompasses four primary subtypes, posing significant health risks. Gaining insights into the global epidemiology of leukemia and its subtypes is crucial for effective resource allocation, clinical guidance, and scientific inquiry.
methodsFrom 1990 to 2021, we analyzed age-standardized rates (ASR) trends across 204 countries and territories, utilizing the estimated annual percentage change (EAPC).
resultsIn 2021, there were approximately 460,000 leukemia cases, 320,000 deaths, and 10.98 million disability-adjusted life years (DALYs). Globally, age-standardized incidence rates (ASIR), mortality rates (ASMR), and DALY rates are on the decline, while age-standardized prevalence rates (ASPR) are rising in high social demographic index (SDI) regions. Men experience a higher leukemia burden compared to women. By subtype, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) predominantly impact older individuals, while acute lymphoblastic leukemia (ALL) primarily affects children. Notably, leukemia ASIR and ASDR reductions are observed in countries with high human development index (HDI).
conclusionAlthough there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. Furthermore, the impact of leukemia varies significantly by region and country, highlighting the urgent need for innovative and personalized prevention and treatment approaches to mitigate this global health issue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.